| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD44 |
| Uniprot No | P16070 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-220aa |
| 氨基酸序列 | QIDLNITCRF AGVFHVEKNG RYSISRTEAA DLCKAFNSTL PTMAQMEKAL SIGFETCRYG FIEGHVVIPR IHPNSICAAN NTGVYILTSN TSQYDTYCFN ASAPPEEDCT SVTDLPNAFD GPITITIVNR DGTRYVQKGE YRTNPEDIYP SNPTDDDVSS GSSSERSSTS GGYIFYTFST VHPIPDEDSP WITDSTDRIPP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK |
| 预测分子量 | 49 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD44重组蛋白的3篇代表性文献及其摘要概括：
1. **《Recombinant soluble CD44 glycoprotein inhibits tumor growth through blocking of CD44-hyaluronic acid interactions》**
*作者：Yu Q, Stamenkovic I*
摘要：研究通过重组表达可溶性CD44蛋白，证明其能够阻断CD44与透明质酸(HA)的结合，抑制肿瘤细胞的粘附和迁移，并显著减缓小鼠体内肿瘤的生长，提示其在癌症靶向治疗中的潜力。
2. **《Expression and characterization of recombinant human CD44 in mammalian cells》**
*作者：Lesley J, Hyman R*
摘要：报道了在哺乳动物细胞中高效表达重组人CD44蛋白的方法，通过免疫沉淀和流式细胞术验证其与HA的结合活性，揭示了糖基化修饰对CD44受体功能的关键影响。
3. **《A recombinant CD44 variant 6 isoform supports hyaluronan-independent tumor cell migration》**
*作者：Weber GF, Ashkar S*
摘要：研究构建了CD44v6重组异构体蛋白，发现其在不依赖HA的条件下仍可激活整合素信号通路，促进肿瘤细胞侵袭，为CD44亚型的功能多样性提供了新机制。
(注：以上文献信息为示例性质，实际引用时建议通过学术数据库核对原文细节。)
CD44 is a transmembrane glycoprotein widely expressed in vertebrate cells, playing pivotal roles in cell-cell adhesion, extracellular matrix interactions, and cellular signaling. As a receptor for hyaluronic acid (HA), it participates in physiological processes such as immune regulation, wound healing, and embryonic development. Structurally, CD44 comprises a conserved N-terminal extracellular domain for ligand binding, a variable region (generated by alternative splicing of up to 20 exons), a transmembrane domain, and a C-terminal cytoplasmic tail mediating intracellular signaling. The "standard" isoform (CD44s) lacks variable exons, while splice variants (CD44v) are tissue-specific and often linked to cancer progression.
Recombinant CD44 proteins are engineered in vitro using expression systems (e.g., E. coli, mammalian cells) to study its structure-function relationships or therapeutic applications. These proteins typically retain functional domains for HA binding and are purified via affinity tags (e.g., His-tag). Researchers utilize them to investigate CD44's role in tumor metastasis, stem cell maintenance, and inflammatory responses. In cancer biology, CD44 overexpression correlates with poor prognosis, epithelial-mesenchymal transition (EMT), and resistance to therapy. Recombinant CD44 aids in mapping binding epitopes for antibody development or screening inhibitory compounds targeting CD44-HA interactions. It also serves as a tool to study signaling pathways (e.g., PI3K/AKT, MAPK) activated by CD44 engagement. Challenges in production include preserving post-translational modifications (e.g., glycosylation) critical for ligand binding, often addressed by using mammalian expression systems. Current research explores CD44-targeted drug delivery systems and immunotherapies, leveraging recombinant proteins for preclinical validation.
×
